-- Results to date demonstrate rapid post-surgical visual recovery with no serious adverse events and meet or exceed FDA target rates for safety and effectiveness –-- Data presented today at Eyecelerator meeting in Park City -- CAMBRIDGE, Mass., May 2, 2025 /PRNewswire/ -- Pykus Therapeutics, Inc. ("Pykus" or the "Company") today announced the presentation of positive clinical data from of its ongoing pilot study evaluating the use of its proprietary, lead product candidate, PYK-2101, a focal hy

Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share

Findings Could Someday Help Prevent Risky Code Insertions into the Human Genome NEW YORK, May 2, 2025 /PRNewswire/ -- Viruses are known to use the genetic machinery of the human cells they invade to make copies of themselves. As part of the process, viruses leave behind remnants throughout the genetic material (genomes) of humans. The virus-like insertions, called "transposable elements," are snippets of genetic material even simpler than viruses that also use host cell machinery to replicate. N

Highlights Continued Progress in Early Detection and the Progression of Esophageal Disease SUFFERN, N.Y., May 2, 2025 /PRNewswire/ -- CDx Diagnostics announced today that new clinical data supporting the utility of the WATS3D test for Barrett's esophagus and dysplasia screening and surveillance has been selected for podium presentation at the 2025 Digestive Disease Week (DDW) in San Diego, the premier conference for gastroenterology professionals. This podium presentation, along with additional

OXFORD, UK I May 1, 2025 I Blue Earth Therapeutics today announced further progress in development of its radiohybrid, lutetium-labelled, PSMA targeted, investigational radioligand therapy, with enrolment of the first two patients in a Phase 2 clinical trial. The primary measure of efficacy in the study will be the proportion of patients achieving a ≥50% reduction in PSA levels, as well as assessing radiographic progression-free survival and patient safety (NCT05413850). The study is testing mul

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKAWAY, NJ, USA I May 02, 2025 I Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2401 multi-center Phase 1 clinical trial evaluating treatment with KH658 for patients with wet Age-related Macular Degeneration (wet AMD). This multi-center, open-label, dose-escalation clini

LOS ANGELES, May 2, 2025 /PRNewswire/ -- Landmark Science, a premier provider of real-world evidence (RWE) solutions, is redefining industry standards with its white-glove, high-touch approach to evidence generation. With long-standing roots in biopharma, Landmark Science bridges the gap between vendors and biopharma, delivering agile and efficient solutions uniquely tailored to clients. This hand-held approach through and through helps clients avoid typical red tape situations that can delay or

在全球贸易形势复杂多变的背景下，医药行业受到的影响日益凸显。众多大型制药企业为应对贸易波动，纷纷加大在美国本土的投入。与此同时，越来越多的生物制药行业领导者开始公开反对特朗普政府的关税政策，礼来公司首席执行官大卫・里克斯（Dave Ricks）便是其中之一。巨额投资本土，质疑关税政策今年 2 月下旬，礼来公司宣布将在美国投入 270 亿美元，并于今年开始建设 4 座新的制造工厂 。这一举措显示出礼来对美国本土市场的重视和信心，旨在实现为美国市场在美国本土生产所有药品的目标。然而，在周四的第一季度财报电话会议上，里克斯却对关税政策提出了质疑。里克斯表示，礼来支持美国政府增加国内投资的目标，但认为关税并非支持本土产业的最佳政策机制 。他主张，“强化” 税收激励措施，或是延长《减税与就业法案》的实施，才是刺激美国经济增长的 “更好工具” 。《减税与就业法案》于 2017 年由特朗普领导的共和党推动实施，其中将美国企业税率从 35% 大幅削减至 21% 。如今，随着针对制药行业的关税威胁成为行业关注焦点，众多生物制药行业领导者都倡导通过税收改革而非关税政策，来促进美国制造业发展和吸引投资。强生

STOCKHOLM, May 2, 2025 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce that The Royal Marsden NHS Foundation Trust in the UK has treated its first patient using a new and groundbreaking workflow, enabled by the new adaptive replanning module, released in the latest version of RayStation®*. The treatment was carried out with Accuray's treatment machine Radixact®, RayStation, and The Royal Marsden's existing oncology information system. The first patient was successfully trea

近日，世界卫生组织（WHO）在成人肥胖症药物使用上的态度转变成为全球医药领域的焦点话题。据路透社独家报道，WHO 正考虑将如 Wegovy 和 Zepbound 等抗肥胖药物列入基本药物清单，这一决策不仅关乎全球肥胖症患者的治疗前景，也对医药行业的发展产生深远影响。WHO 态度转变，拟纳入肥胖症药物根据路透社的报道，WHO 在一份内部备忘录中表达了对将某些抗肥胖药物列入基本药物清单的支持，这其中就包括诺和诺德的 Wegovy 和礼来的 Zepbound 。此前，在 2023 年的基本药物清单更新中，这些药物并未被列入 。WHO 通常每两年根据专家委员会的建议发布一次基本药物清单，清单上的药物被认为能够 “满足人群的优先医疗保健需求”，并且应在 “正常运转的卫生系统中随时可得” 。此次 WHO 的态度转变，意味着这些在全球广受欢迎的肥胖症药物有望获得更广泛的认可和应用。药物价格成阻碍，呼吁改善可及性然而，随着这一决策意向的披露，药物的可及性问题也浮出水面。以 Wegovy 和 Zepbound 为例，每月的治疗费用可能超过 1000 美元，具体价格会因实际处方和保险计划而有所不同 。对于